文献速递血栓与止血

预防和根除血友病A抑制物的贝叶斯平台试验设计

The design of a Bayesian platform trial to prevent and eradicate inhibitors in patients with hemophilia.
PubMed 文献 · Blood Adv · 2020-01-01

针对血友病A抑制物预防与根除的最佳方案不确定且经典试验在罕见病中不可行,设计了2项48周随机试验比较ELOCTATE与emicizumab。采用贝叶斯先验、分段指数生存模型和模拟优化设计,主要终点为抑制物形成或根除概率,模拟显示预防试验66例有84%把握度检验非劣效,根除试验90例有80%把握度检验优效。

要点

  • 平台设计整合贝叶斯先验与模拟,提高罕见病试验统计与行政效率。
  • 预防试验66例,若emicizumab真优10%,有84%把握度检验10%非劣效界值。
  • 根除试验90例,有80%把握度检验ELOCTATE免疫耐受诱导联合emicizumab的15%优效性。

核心结论

  • 平台设计可为INHIBIT试验提供统计与行政效率,比较emicizumab与ELOCTATE预防和根除抑制物。

研究设计与样本

  • 设计2项48周随机试验,分别比较ELOCTATE与emicizumab预防和根除抑制物。
  • 采用历史数据作为贝叶斯先验,允许优先随机至emicizumab,并用分段指数生存模型估计各臂抑制物形成的均值与95%CI。
  • 通过模拟确定最佳模型设计以优化把握度。

主要发现

  • 模拟显示预防试验66例,若emicizumab真优10%,有84%把握度检验其相对ELOCTATE的10%非劣效界值。
  • 模拟显示根除试验90例,有80%把握度检验ELOCTATE免疫耐受诱导联合与不联合emicizumab的15%优效性。

关键数值与推荐

  • 预防试验主要终点为抑制物形成概率,根除试验主要终点为抑制物根除概率。
  • 设计包含emicizumab臂压倒性优效的早期停止规则。

临床怎么用

  • 该平台设计可用于在罕见病患者中高效开展抑制物预防与根除的随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Among individuals with the rare congenital bleeding disorder hemophilia A, the major challenge is inhibitor formation, which is associated with significant morbidity and cost. Yet, as the optimal approach to prevent and eradicate inhibitors is not known, we are at equipoise. Because classic trial design is not practical in a rare disease setting, we designed 2 48-week randomized trials comparing ELOCTATE and emicizumab to prevent and eradicate inhibitors. To achieve statistical efficiency, we incorporated historic data (Bayesian priors) on inhibitor formation to allow preferential randomization to emicizumab, piecewise exponential survival models to determine mean and 95% confidence interval for inhibitor formation in each arm, and simulations to determine the best model design to optimize power. To achieve administrative efficiency, the trials will be performed with the same sites, staff, visit frequency, blood sampling, laboratories, and laboratory assays, with streamlined enrollment so patients developing inhibitors in the first trial may be enrolled on the second trial. The primary end point is the probability of inhibitor formation or inhibitor eradication, respectively. The design indicates early stopping rules for overwhelming evidence of superiority of the emicizumab arms. Simulations indicate that, with 66 subjects, the Prevention Trial will have 84% power to detect noninferiority of emicizumab to ELOCTATE with a margin of 10% if emicizumab is truly 10% superior to ELOCTATE; with 90 subjects, the Eradication Trial will have 80% power to detect 15% superiority of ELOCTATE immune tolerance induction with vs without emicizumab. Thus, a platform design provides statistical and administrative efficiency to conduct INHIBIT trials.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bertolet M, Brooks MM, Ragni MV, et al. The design of a Bayesian platform trial to prevent and eradicate inhibitors in patients with hemophilia. Blood Adv. 2020. PMID: 33156923. doi:10.1182/bloodadvances.2020002789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。